Kathleen M Coen1, K Laurel Adamson, William A Corrigall. 1. Smoking and Nicotine Dependence Research Unit, Department of Neuroscience, Centre for Addiction & Mental Health, Toronto, ON, M5S 2S1, Canada.
Abstract
RATIONALE: The use of animal models to study existing medications for smoking cessation can elucidate the mechanism(s) of action of cessation agents and further validate the models for medication development. OBJECTIVE: The objective of the study was to evaluate the response of nicotine self-administration (NSA) to pharmacological agents related to the smoking cessation medication bupropion and to nicotine dosing mimicking nicotine replacement on fixed-ratio (FR) and progressive-ratio (PR) schedules of reinforcement. MATERIALS AND METHODS: NSA was maintained at a nicotine dose of 30 microg/kg/infusion i.v. in rats trained on FR5 and PR40% schedules. Pharmacological manipulations related to bupropion were examined by treating animals with a dopamine reuptake inhibitor [GBR 12909 (GBR)], a norepinephrine reuptake inhibitor [nisoxetine (NIS)], and a nicotinic antagonist [dihydro-beta-erythroidine (DHbetaE)]. The effect of nicotine replacement was examined on the PR schedule by chronic dosing with osmotic minipumps. RESULTS: Significant treatment effects occurred with NIS and combinations of NIS-DHbetaE and with GBR on response rates. Chronic nicotine dosing reduced self-administration. The two schedules yielded different results with some treatments. CONCLUSIONS: Noradrenergic-nicotinic cholinergic interactions and enhanced responding consequent to dopamine reuptake inhibition may be part of the complex behavioral pharmacology of bupropion-like compounds. Observation of differential results with the two schedules has implication for the use of self-administration techniques to elaborate the mechanisms of dependence as well as drug discovery.
RATIONALE: The use of animal models to study existing medications for smoking cessation can elucidate the mechanism(s) of action of cessation agents and further validate the models for medication development. OBJECTIVE: The objective of the study was to evaluate the response of nicotine self-administration (NSA) to pharmacological agents related to the smoking cessation medication bupropion and to nicotine dosing mimicking nicotine replacement on fixed-ratio (FR) and progressive-ratio (PR) schedules of reinforcement. MATERIALS AND METHODS: NSA was maintained at a nicotine dose of 30 microg/kg/infusion i.v. in rats trained on FR5 and PR40% schedules. Pharmacological manipulations related to bupropion were examined by treating animals with a dopamine reuptake inhibitor [GBR 12909 (GBR)], a norepinephrine reuptake inhibitor [nisoxetine (NIS)], and a nicotinic antagonist [dihydro-beta-erythroidine (DHbetaE)]. The effect of nicotine replacement was examined on the PR schedule by chronic dosing with osmotic minipumps. RESULTS: Significant treatment effects occurred with NIS and combinations of NIS-DHbetaE and with GBR on response rates. Chronic nicotine dosing reduced self-administration. The two schedules yielded different results with some treatments. CONCLUSIONS: Noradrenergic-nicotinic cholinergic interactions and enhanced responding consequent to dopamine reuptake inhibition may be part of the complex behavioral pharmacology of bupropion-like compounds. Observation of differential results with the two schedules has implication for the use of self-administration techniques to elaborate the mechanisms of dependence as well as drug discovery.
Authors: Mark G LeSage; Dan E Keyler; Don Shoeman; Donna Raphael; Gregory Collins; Paul R Pentel Journal: Pharmacol Biochem Behav Date: 2002-05 Impact factor: 3.533
Authors: H Rollema; L K Chambers; J W Coe; J Glowa; R S Hurst; L A Lebel; Y Lu; R S Mansbach; R J Mather; C C Rovetti; S B Sands; E Schaeffer; D W Schulz; F D Tingley; K E Williams Journal: Neuropharmacology Date: 2006-12-08 Impact factor: 5.250
Authors: Mark G LeSage; Jennifer L Perry; Catherine M Kotz; David Shelley; William A Corrigall Journal: Psychopharmacology (Berl) Date: 2010-02-24 Impact factor: 4.530
Authors: Edward D Levin; Corinne Wells; Joshua E Johnson; Amir H Rezvani; Frank P Bymaster; Jed E Rose Journal: Eur J Pharmacol Date: 2015-06-20 Impact factor: 4.432
Authors: Elysia Small; Hina P Shah; Jake J Davenport; Jacqueline E Geier; Kate R Yavarovich; Hidetaka Yamada; Sreedharan N Sabarinath; Hartmut Derendorf; James R Pauly; Mark S Gold; Adrie W Bruijnzeel Journal: Psychopharmacology (Berl) Date: 2009-11-21 Impact factor: 4.530
Authors: Matthew I Palmatier; Melissa E Levin; Kara L Mays; Eric C Donny; Anthony R Caggiula; Alan F Sved Journal: Psychopharmacology (Berl) Date: 2009-09-17 Impact factor: 4.530